A SYNTHESIS OF URBAN TRAVEL PATTERNS IN METROPOLITAN LAFAYETTE

Bavey,S. F.,Hill,J.,F.,McLaughlin,B.,Mendenhall,D. R.,Miles,C. J.,Oppenlander,W.,P.,Privette

Abstract:vii

What problem does this paper attempt to address?

Early Intestinal Rehabilitation Therapy Ameliorates Intestinal Adaptation in Children with Short Bowel Syndrome: The Long-Term Outcome

Mingxiao Guo,Chunlei Lu,Yousheng Li

DOI: https://doi.org/10.1177/000313481608201229

2016-12-01

The American Surgeon

Abstract:In the management of short bowel syndrome (SBS), the benefits of treatment with growth hormone (GH), glutamine, and enteral nutrition (EN) on intestinal adaptation among children patients is still controversial. The aim of present study is to determine whether GH, glutamine, and EN have positive effect on intestinal adaptation in children with SBS. Sixteen children with SBS (small bowel remnant length, 56.75 ± 8.09 cm; mean ± SE) were treated with GH (0.05 mg/kg/d), glutamine (0.45 mg/kg/d), plus EN-enriched fiber diet for four weeks. After four weeks of treatment, patients were discharged home; GH was discontinued, but the EN with glutamine was continued. Repeated treatment was performed if there were lose weight, dysplasia, or severe diarrhea. All patients completed the treatment. Body weight, intestinal absorptive capacity, and plasma levels of proteins were significantly improved after complete treatment, without any major adverse effects. On follow-up, no death was reported. Treatment with GH, glutamine, and EN in early stage significantly improved intestinal adaptation in pediatric patients with SBS. Furthermore, the positive effect of the treatment does not seem to be sustained once GH discontinued until the residual intestinal adaptation reaches its maximum.
Cisapride Prevents Enteric Bacterial Overgrowth and Translocation by Improvement of Intestinal Motility in Rats with Acute Liver Failure

X. D. Wang,V. Soltesz,R. Andersson

DOI: https://doi.org/10.1159/000129484

1996-01-01

European Surgical Research

Abstract:Enteric bacterial overgrowth resulting from compromised gastrointestinal motility has been suggested to be important for the development of enteric bacterial translocation. In the present study, the effect of cisapride, a 5-hydroxytryptamine-4-receptor agonist and stimulant of intestinal motility, was evaluated concerning intestinal motility, as measured by intestinal transit time, enteric bacterial overgrowth, and bacterial translocation from the gut in rats with acute liver failure induced by 90% hepatectomy. The results demonstrated that (1) the incidence of bacterial translocation to the systemic and portal circulation as well as to the liver, spleen, kidneys, and lungs was nil, and 17-33% to MLN in hepatectomized animals treated with cisapride, i.e. significantly lower than in hepatectomized rats administered saline; (2) overgrowth of E. coli in the intestine was noted in hepatectomized animals given saline, but not following cisapride treatment; (3) cisapride improved the otherwise delayed intestinal transit time following hepatectomy as shown by an increase in the leading edge of isotopic propulsion and the linear slope of the cumulative percent of radioactivity through each intestinal segment. Thus, we conclude that intravenous administration of cisapride prevents enteric bacterial overgrowth and bacterial translocation by improving intestinal motility in rats with acute liver failure induced by subtotal hepatectomy.
Influence of Cisapride on Gastric Emptying of Solids and Liquids Monitored by 13C Breath Tests.

Li-Ping Duan,Barbara Braden,Wolfgang F. Caspary,Bernhard Lembcke

DOI: https://doi.org/10.1007/bf02209007

IF: 29.4

1995-01-01

Gastroenterology

Abstract:[13C]Acetate and [13C]octanoate breath tests were used to analyze the gastric emptying of liquids and solids in healthy controls and patients with functional dyspepsia both with and without cisapride. A standard test meal was labeled with either 150 mg [13C]acetate (liquid phase labeled in the water) or with 100 mg [13C]octanoate (solid phase labeled in the egg yolk). Six patients with dyspepsia and six healthy controls underwent a 4-hr breath test four times, ie, both the [13C]acetate and [13C]octanoate test with and without cisapride. Duplicate [13C]acetate or [13C]octanoate breath tests were performed in another 12 healthy controls in order to assess day-to-day variability of gastric emptying for liquids and solids. The mass spectrometric data were fitted to a power exponential function allowing mathematical analysis of half-emptying times and lag times. In patients with dyspepsia, gastric half emptying times of solids were significantly delayed as compared to the emptying of solids in the controls (203±41 vs 148±35 min;P<0.05). With cisapride, gastric emptying of solids was significantly accelerated (P<0.05) both in the patients (166±58 min) and in the controls (117±27 min). The gastric emptying of liquids did not differ in patients and controls, and cisapride had no effect on the emptying of liquids within the normal range. In the healthy controls, half emptying times both for liquids and solids were reproducible on the two different days (CVintra: 5.58% for liquis, 20.01% for solids). We conclude that as an entirely noninvasive and nonradioactive tool13C-labeled breath tests are well reproducible and allow assessment of the effect of cisapride on the characteristics of gastric emptying.
Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children

Leonel Rodriguez,Juan Diaz,Samuel Nurko

DOI: https://doi.org/10.1016/j.jpeds.2012.12.096

Abstract:Objective: To present our experience using cyproheptadine, a potent serotonin antagonist used to stimulate appetite, to treat dyspeptic symptoms in children. Study design: This was a retrospective open-label study conducted to evaluate the safety and efficacy of cyproheptadine in children with refractory upper gastrointestinal symptoms (eg, nausea, early satiety, vomiting, retching after fundoplication, abdominal pain). Response was graded as resolution if symptoms resolved and medication was discontinued, as significant improvement if symptoms resolved with no further interventions, and as failure with any other outcome. Results: A total of 80 children (65% females) aged <12 years (mean age, 10 years) were included. Response to therapy was reported in 55% of patients. Multivariate analysis revealed better response in children and females (P = .04 and .03, respectively). No associations were found between response to therapy response and gastric emptying, antroduodenal manometry, functional dyspepsia, vomiting, and use of cyproheptadine as first therapy. Early vomiting (occurring within 1 hour after starting a meal) responded better than late vomiting (P = .03), and patients with retching after undergoing Nissen fundoplication had an 86% response rate. Twenty-four patients (30%) complained of side effects, all mild, including somnolence (16%), irritability and behavioral changes (6%), increased appetite and weight gain (5%), and abdominal pain (2.5%), but only 2 of these patients discontinued therapy. Multivariate analysis demonstrated an association between side effects and lack of response to therapy (P = .04), but no associations with age and sex. Conclusion: Cyproheptadine is safe and effective for treating dyspeptic symptoms in children, particularly in young children and those with early vomiting and retching after fundoplication.
A Review of Enteral Strategies in Infant Short Bowel Syndrome: Evidence-based or NICU Culture?

Malki Miller,Sathyaprasad Burjonrappa

DOI: https://doi.org/10.1016/j.jpedsurg.2013.01.023

IF: 2.549

2013-05-01

Journal of Pediatric Surgery

Abstract:INTRODUCTION: Short bowel syndrome (SBS) is an increasingly common condition encountered across neonatal intensive care units. Improvements in parenteral nutrition (PN), neonatal intensive care and surgical techniques, in addition to an improved understanding of SBS pathophysiology, have contributed in equal parts to the survival of this fragile subset of infants. Prevention of intestinal failure associated liver disease (IFALD) and promotion of intestinal adaptation are primary goals of all involved in the care of these patients. While enteral nutritional and pharmacological strategies are necessary to achieve these goals, there remains great variability in the application of therapeutic strategies in units that are not necessarily evidence-based.MATERIALS AND METHODS: A search of major English language medical databases (SCOPUS, Index Medicus, Medline, and the Cochrane database) was conducted for the key words short bowel syndrome, medical management, nutritional management and intestinal adaptation. All pharmacological and nutritional agents encountered in the literature search were classified based on their effects on absorptive capacity, intestinal adaptation and bowel motility that are the three major strategies employed in the management of SBS. The Oxford Center for Evidence-Based Medicine (CEBM) classification for levels of evidence was used to develop grades of clinical recommendation for each variable studied.RESULTS: We reviewed various medications used and nutritional strategies included soluble fiber, enteral fat, glutamine, probiotics and sodium supplementation. Most interventions have scientific rationale but little evidence to support their role in the management of infant SBS. While some of these agents symptomatically improve diarrhea, they can adversely influence pancreatico-biliary function or actually impair intestinal adaptation. Surgical anatomy and liver function are two important variables that should determine the selection of pharmacological and nutritional interventions.DISCUSSION: There is a paucity of research investigating optimal clinical practice in infant SBS and the little evidence available is consistently of lower quality, resulting in a wide variation of clinical practices among NICUs. Prospective trials should be encouraged to bridge the evidence gap between research and clinical practice to promote further progress in the field.

pediatrics,surgery
Polyvalent DNA vaccines with bidirectional promoters

M. Kwissa,J. Unsinger,R. Schirmbeck,H. Hauser,J. Reimann

DOI: https://doi.org/10.1007/s001090000135

2000-09-19

Journal of Molecular Medicine

Abstract:
Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis

Shun-Cai Zhang,Wei Wang,Wei-Ying Ren,Bo-Ming He,Kang Zhou,Wu-Nan Zhu

DOI: https://doi.org/10.3748/wjg.v9.i3.534

Abstract:Aim: To investigate the effects of cisapride on intestinal bacterial overgrowth (IBO), bacterial and endotoxin translocation, intestinal transit and permeability in cirrhotic rats. Methods: All animals were assessed with variables including bacterial and endotoxin translocation, intestinal bacterial overgrowth, intestinal transit and permeability. Bacterial translocation (BT) was assessed by bacterial culture of MLN, liver and spleen, IBO by a jejunal bacterial count of the specific organism, intestinal permeability by determination of the 24-hour urinary (99m)Tc-DTPA excretion and intestinal transit by measurement of the distribution of (51)Cr in the intestine. Results: Bacterial translocation (BT) and IBO was found in 48 % and 80 % cirrhotic rats respectively and none in control rats. Urinary excretion of (99m)Tc-DTPA in cirrhotic rats with BT (22.2+/-7.8) was greater than these without BT (10.5+/-2.9). Intestinal transit (geometric center ratio) was significantly delayed in cirrhotic rats (0.31+/-0.06) and further more delayed in cirrhotic rats with BT (0.24+/-0.06) than these without BT (0.38+/-0.11). Cirrhotic rats with IBO had significantly higher rates of intestinal bacterial and endotoxin translocation, slower intestinal transit time and higher intestinal permeability than those without IBO. It was also found that BT was closely associated with IBO and the injury of intestinal barrier. Compared with the placebo group, cisapride-treated rats had lower rates of bacterial/endotoxin translocation and IBO, which was closely associated with increased intestinal transit and improved intestinal permeability by cisapride. Conclusion: These results indicate that endotoxin and bacterial translocation in cirrhotic rats may be attributed to IBO and increased intestinal permeability. Cisapride that accelerates intestinal transit and improve intestinal permeability might be helpful in preventing intestinal bacterial and endotoxin translocation.
Impact of intestinal lengthening on the nutritional outcome for children with short bowel syndrome

R Figueroa-Colon,P R Harris,E Birdsong,F A Franklin,K E Georgeson

DOI: https://doi.org/10.1016/s0022-3468(96)90409-1

Abstract:Survival among children with short bowel syndrome has increased with the use of supportive nutritional techniques including parenteral and enteral nutrition. Further improvement in outcome has been sought by using intestinal lengthening procedures to lengthen the bowel, improve intestinal motility, initiate a progressive increase in intestinal mucosal mass, and thereby improve tolerance to enteral nutrition. The authors examine the growth parameters and the tolerance to enteral nutrition in children with refractory short bowel syndrome before and after intestinal lengthening procedures. For seven children, the percentage of calories from enteral nutrition, the medical and surgical complications, and the number of days in the hospital (1 year before and 2 years after the lengthening procedure) were evaluated. The mean birth weight was 1,991 g (range, 1,198 to 3,096 g). The initial diagnoses requiring bowel resection included necrotizing enterocolitis, multiple small bowel atresias, gastroschisis with midgut volvulus, cloacal exstrophy, and long-segment Hirschsprung's disease. The mean length of the residual small bowel was 49 cm (range, 6 to 92 cm). All but one child had surgical resection of the ileocecal valve. The percentage of enteral nutrition calories significantly increased by 9 months after the procedure (P < .008, analysis of variance). Only one child has been completely weaned from parenteral nutrition. All children's growth parameters have been maintained or improved (weight/age, height/age, and weight/height). Few major medical and surgical complications have been observed. Central venous catheter infection has been the most common medical complication. The mean number of hospitalization days decreased during the second year after the lengthening procedure. The authors conclude that the intestinal lengthening procedure enhances the tolerance for enteral nutrition, improves the nutritional status, and decreases the need for hospitalization. The procedure should be considered for children with refractory short bowel syndrome who require prolonged parenteral nutrition.
Effect of Growth Hormone, Glutamine, and Enteral Nutrition on Intestinal Adaptation in Patients with Short Bowel Syndrome

Mingxiao Guo,Yousheng Li,Jieshou Li

DOI: https://doi.org/10.1016/s1744-1161(10)70127-7

2013-01-01

The Turkish Journal of Gastroenterology

Abstract:Background/aims: In the management of short bowel syndrome, the benefits of treatment with growth hormone, glutamine, and enteral nutrition for intestinal adaptation is still controversial. The aim of the current study was to determine whether growth hormone, glutamine, and enteral nutrition had positive effect on intestinal adaptation. Materials and Method: Twelve patients with short bowel syndrome (small-bowel remnant length, 59 +/- 9 cm; mean +/- SEM) received growth hormone (0.05 mg/kg/day), oral glutamine (30 g/day), plus enteral nutrition for 4 weeks. Intestinal absorptive capacity and biochemical parameters were investigated before treatment and after treatment. Body composition was determined by bioelectric impedance analysis. Result: All patients completed the treatment. Intestinal absorptive capacity and plasma levels of proteins were significantly improved after treatment. Body weight, lean body mass, total body water, and body cell mass also increased without any major adverse effects. At the 3-month follow-up, the nutritional status of patients was also well maintained, and there was no death during this period. Conclusion: Four weeks of intestinal rehabilitation therapy significantly improved intestinal absorption if appropriate patient with short bowel syndrome was selected.
Treatment of Erythromycin and Cisapride for Neonates with Feeding Intolerance

黄瑛,邵肖梅,曾纪骅,赵瑞芳,季志英,袁红

DOI: https://doi.org/10.3969/j.issn.1672-8467.2001.05.015

2001-01-01

Abstract:Purpose: To investigate the effects of erythromycin and cisapride promoting neonatal gastrointestinal motility and improving neonatal feeding. Methods: During the year of Nov. 1997 to Feb. 1999,41 hospitalized neonates which were suffered from feeding problems were studied. Erythromycin (3-5)mg/(kg·d) by intravenous infusion and 0.1% solution of cisapride (0.2-0.3)ml/kg, three times a day by oral were used in our study. Gastroesophageal scintigraphy and radioimmuno assay were measured before and after the intervention. Results: 27 neonates were treated with erythromycin for (7.8 ± 2.2) d, after that GE60% was increased from (22.9 ± 12.6)% to (38.7+17.1)%, RI was decreased from 16.9 ± 9.4 to 8.1 ± 5.7, P < 0. 001; plasma motilin was incerased significantly [from (583.2 ± 253.1) to (907.5 ± 301.1)pg/ml, P < 0.001] but senan gastrin didn't change greatly [(52.8 ± 12.9) vs (58.7 ± 20.4)pg/ml, P > 0.05].14 neonates took cisapride for (9.4 ± 2.2) d, GE60% was increased from (26.2 ± 14.7)% to (40.0 ± 17.4)%, RI was decreased from 17.3 ± 11.4 to 7.2 ± 3.5, (P < 0.01). But blood leve] of gastrin and motilin didn't change significantly. After treatment, there was no difference of the volume of milk taken between the two groups (176.2 ± 49.4)ml/(kg·d) in erythromycin group and (197.5 ± 35.8) ml/(kg·d) in cisapride group, (P > 0.05). There were no obvious side effects of the two drugs in this study. Conclusions: Erythromycin and cisapride can promote neonatal gastrointestinal motility and improve their feeding. How to choose these drugs depends on the specific situations.
Outcomes of Children With Short Bowel Syndrome: Experiences in a Multidisciplinary Intestinal Rehabilitation Unit Over Two Decades

Jaime Tsz-Wing Tsang,Adrian Chi-Heng Fung,Stephen Cheuk-Lam Lau,Kenneth Kak-Yuen Wong

DOI: https://doi.org/10.1016/j.jpedsurg.2024.07.031

2024-07-24

Abstract:Background: Short bowel syndrome (SBS) is a rare but serious form of organ failure, and patients with SBS depend on total parenteral nutrition (PN) to maintain growth and development. The present study aimed to evaluate the experiences and outcomes of children with SBS managed by a multidisciplinary intestinal rehabilitation programme in a tertiary paediatric centre. Methods: A retrospective single-centre analysis of all paediatric patients with a clinical diagnosis of SBS between 2001 and 2022 was performed. Clinical outcomes and their predictors were extracted and analysed. Results: Of the 64 children included in the study, 43 (67%) had extensive necrotising enterocolitis. The median bowel length was 45 cm (interquartile range (IQR) = 18-65) and 18.9% (IQR = 10-28.5) of the expected length based on age. Over a mean follow-up period of 8.9 years, 57 patients (89%) survived, and 50 (78%) weaned off PN. The presence of intestinal failure-associated liver disease (IFALD) (OR = 6.375, p = 0.02) and patients managed before the introduction of fish oil-based PN in 2007 (OR = 5.895, p = 0.001) were significant predictors of mortality. There was an overall improvement in survival over time (p = 0.003). Ultrashort bowel length was not associated with significantly higher mortality (OR = 1.1, p = 0.65) but was a poor prognostic factor for weaning off PN (OR = 3.57, p = 0.004). Among all patients who weaned off PN, two had bowel lengthening procedures and one received a glucagon-like peptide 2 (GLP-2) analogue. Conclusions: A multidisciplinary intestinal rehabilitation programme offers a comprehensive approach for patients with SBS and has been shown to be effective with favourable outcomes. Improvements in the choice of PN and the development of new treatment strategies potentially improved the survival and enteral autonomy of SBS patients. Level of evidence: III.
Serial Transverse Enteroplasty (STEP) for Short Bowel Syndrome (SBS) in Children: A Multicenter Study on Long-term Outcomes

Claire Dagorno,Louise Montalva,Carmen Capito,Frederic Lavrand,Audrey Guinot,Stéphan De Napoli Cocci,Thomas Gelas,Rémi Dubois,Anne Dariel,Emmanuelle Dugelay,Christophe Chardot,Arnaud Bonnard

DOI: https://doi.org/10.1016/j.jpedsurg.2024.161909

2024-09-26

Abstract:Objectives: Short Bowel Syndrome (SBS), secondary to various underlying diseases, is one of the main causes of intestinal failure in children. Surgical management by serial transverse enteroplasty (STEP), is feasible in selected cases, but results on long-term follow-up are scarce. The aim of this study was to report long-term outcomes of the STEP procedure in children with SBS. Methods: We performed a multicenter national retrospective study reviewing medical charts of children who underwent a STEP technique between 2000 and 2022 in 6 university hospitals. Collected data included demographics, SBS history, surgical procedures, nutritional support (enteral or parenteral), STEP management, complications, and outcomes (nutritional support, digestive symptoms, growth). Results: STEP was performed in 36 SBS, resulting from 14 gastroschisis, 10 intestinal atresia, 8 necrotizing enterocolitis (NEC), 2 midgut volvulus, and 2 intestinal Hirschsprung disease. Median age at first STEP was 10.8 months [4.5; 63.8]. Bowel length significantly increased (47 vs 70 cm, p < 0.01), with a median gain of 16 cm [11; 25] or 34%. At surgery, 33 children had parenteral nutrition (PN). A second STEP was performed in 11 patients, at a median age of 4.2 years [2.8; 6.8]. One patient underwent a third STEP. Two children required intestinal transplantation. Median follow-up was 7 years [4.4;11.4]. Out of 33 children requiring PN before surgery, 14 children were weaned off PN. The remaining 19 children still required PN, but their dependency decreased by 19%. Out of 17 children presenting severe intestinal dilations and bacterial overgrowth, 12 became asymptomatic. Out of 20 with chronic obstructive symptoms, 8 patients still required supplementary PN whereas 12 achieved complete enteral autonomy, including 3 requiring supplementary enteral support. Conclusion: STEP technique remains a surgical option in the management of these children, enabling a decrease in PN dependency, resulting in weaning off PN in some cases, as well as an improvement of clinical symptoms. Type of study: Retrospective multicenter observational study. Level of evidence: Level 3.
Commentary: Endovascular Repair of Postdissection Aneurysms Involving the Thoracoabdominal Aorta

S. Haulon,D. Fabre,J. Sobocinski,R. Clough

DOI: https://doi.org/10.1177/1526602816679333

IF: 2.6

2017-02-01

Journal of Endovascular Therapy

Abstract:We would like to congratulate Xiong and colleagues for reporting an innovative technique that allowed the successful treatment of a complex thoracoabdominal aortic dissection (TAAD) in an acute setting. This case confirms that thoracic endovascular aortic repair (TEVAR) of acute or chronic dissection does not always promote aortic remodeling; rather, remodeling is often limited to the level of the endograft. TEVAR should thus be carefully considered, as it may not prevent further aortic growth, and it is associated with significant risks, such as stroke and spinal cord ischemia. Nonetheless, it is our first line therapy in patients with life-threatening complications, such as rupture, malperfusion in acute cases, and significant aneurysmal dilatation of the false lumen in chronic cases. After TEVAR, the endograft’s distal edge can tear the flap and create a stent-graft–induced new entry (SINE). This will increase the flow in the false lumen, resulting in high pressure and aneurysmal evolution, as was seen in this case. We see many patients in our clinic with TAAD and aneurysmal evolution after TEVAR for type B dissection and chose to treat them in this non-acute setting using custom-made fenestrated and/or branched endografts. The 6-week manufacturing delay in this context is not an issue. We favor fenestrated (Figure 1) over branched devices because the latter is associated with prolonged access through the aortic arch, and in a narrow true lumen there may be a conflict between the branches and the aortic endograft. It is worth noting, however, that the true lumen often changes configuration at the end of the procedure once all communications between true and false lumens have been covered by the endograft, resulting in depressurization of the false lumen; the true lumen configuration transforms from a French croissant to an American donut instantly once the false lumen is no longer pressurized. Connecting the origin of target vessels located in the false lumen to their respective fenestrations can be challenging and at times impossible. A tear in the dissection flap is almost always depicted at the level of the target vessel origin, and we therefore design the endograft (implanted in the true lumen) with the fenestration positioned in front of the tear. The case described by Xiong et al is rare because the communications between the true and false lumens at the level of the visceral aorta had sealed. The large entry tear above diverted the majority of the flow to the false lumen, which supplied the celiac trunk, superior mesenteric artery (dual supply with true lumen), and left renal artery. In cases such as these, we have occasionally used a similar approach, with branches positioned above the large entry tear that are then connected to the visceral target vessels perfused by the false lumen with numerous and long bridging stents (Figure 2). The long-term patency of these very long branches is, however, questionable. In Xiong et al, the images in Figure 2B and C show thrombus formation and compression of the branches. It is of paramount importance to understand that the technique described by Xiong et al had a favorable outcome only because the communications between the lumens had sealed following creation of the large entry tear by the distal edge of the thoracic endograft. In most cases, the false lumen would have been perfused and pressurized through the entry tears located at the level of the visceral aorta, and the patient would have remained at risk of 679333 JETXXX10.1177/1526602816679333Journal of Endovascular TherapyHaulon et al research-article2016
Effects of Bowel Rehabilitation and Combined Trophic Therapy on Intestinal Adaptation in Short Bowel Patients.

GH Wu,ZH Wu,ZG Wu

DOI: https://doi.org/10.3748/wjg.v9.i11.2601

2003-01-01

Abstract:AIM: To evaluate the effects of bowel rehabilitation and combined trophic therapy on intestinal adaptation in short bowel patients.METHODS: Thirty-eight patients with severe short-bowel syndrome (SBS) were employed in the present study, whose average length of jejunum-ileum was 35.8+/-21.2 cm. The TPN treatment was initiated early to attain positive nitrogen balance and prevent severe weight loss. The TPN composition was designated to be individualized and altered when necessary. Enteral feeding was given as soon as possible after resection and increased gradually. Meals were distributed throughout the day. Eight patients received treatment of growth hormone (0.14 mg/kg.day) and glutamine (0.3 g/kg.day) for 3 weeks. D-xylose test, N-15-Gly trace test and C-13-palmitic acid breath test were done to determine the patients' absorption capability.RESULTS: Thirty-three patients maintained well body weight and serum albumin concentration. The average time of follow-up for 33 survival patients was 5.9+/-4.3 years. Twenty-two patients weaned from TPN with an average TPN time of 9.5+/-6.6 months. Two patients, whose whole small bowel, ascending and transverse colon were resected received home TPN. An other 9 patients received parenteral or enteral nutritional support partly as well as oral diet. Three week rhGH+GLN therapy increased nutrients absorption but the effects were transient.CONCLUSION: By rehabilitation therapy, most short bowel patients could wean from parenteral nutrition. Dietary manipulation is an integral part of the treatment of SBS. Treatment with growth hormone and glutamine may increase nutrients absorption but the effects are not sustained beyond the treatment period.
Teduglutide for pediatric short bowel syndrome patients

Beatrice E. Rosete,Danielle Wendel,Simon P. Horslen

DOI: https://doi.org/10.1080/17474124.2021.1913052

2021-04-26

Abstract:Introduction: The goal for pediatric short bowel syndrome (SBS) patients is intestinal adaptation. Until recently, the medical management of pediatric SBS has centered on the prevention and treatment of complications in order to allow time for adaptation. Teduglutide, glucagon-like peptide 2 (GLP-2) analog, has recently been approved for use in pediatric SBS patients greater than 1 year of age as a novel agent to augment intestinal adaptation. Areas covered: This article reviews the pharmacology, safety, efficacy, and tolerability of GLP-2 analog teduglutide in pediatric patients greater than 1 year of age. We review all current studies and discuss teduglutide's place in pediatric SBS therapy. Expert opinion: Teduglutide marks the first successful pharmacological intervention that augments the natural process of adaptation safely and effectively in SBS pediatric patients. More studies and further development are needed to optimize its potential in other pediatric patients.

gastroenterology & hepatology
Long‐term teduglutide associated with improved response in pediatric short bowel syndrome‐associated intestinal failure

Paul W. Wales,Susan Hill,Ian Robinson,Bram P. Raphael,Cheney Matthews,Valeria Cohran,Beth Carter,Robert Venick,Samuel Kocoshis

DOI: https://doi.org/10.1002/jpn3.12276

2024-06-16

Journal of Pediatric Gastroenterology and Nutrition

Abstract:Objectives Patients with short bowel syndrome‐associated intestinal failure (SBS‐IF) require long‐term parenteral nutrition and/or intravenous fluids (PN/IV) to maintain fluid or nutritional balance. We report the long‐term safety, efficacy, and predictors of response in pediatric patients with SBS‐IF receiving teduglutide over 96 weeks. Methods This was a pooled, post hoc analysis of two open‐label, long‐term extension (LTE) studies (NCT02949362 and NCT02954458) in children with SBS‐IF. Endpoints included treatment‐emergent adverse events (TEAEs) and clinical response (≥20% reduction in PN/IV volume from baseline). A multivariable linear regression identified predictors of teduglutide response; the dependent variable was mean change in PN/IV volume at each visit over 96 weeks. Results Overall, 85 patients were analyzed; 78 patients received teduglutide in the parent and/or LTE studies (any teduglutide [TED] group), while seven patients did not receive teduglutide in either the parent or LTE studies. Most TEAEs were moderate or severe in intensity in both groups. By week 96, 82.1% of patients from the any TED group achieved a clinical response, with a mean fluid decrease of 30.1 mL/kg/day and an energy decrease of 21.6 kcal/kg/day. Colon‐in‐continuity, non‐White race, older age at baseline, longer duration of teduglutide exposure, and increasing length of remaining small intestine were significantly associated with a reduction in mean PN/IV volume requirements. Conclusions In pediatric patients with SBS‐IF, teduglutide treatment resulted in long‐term reductions in PN/IV requirements. The degree of PN/IV volume reduction depended on the duration of teduglutide exposure, underlying bowel anatomy, and demographics.

pediatrics,gastroenterology & hepatology,nutrition & dietetics
Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study

Samuel A. Kocoshis,Russell J. Merritt,Susan Hill,Susan Protheroe,Beth A. Carter,Simon Horslen,Simin Hu,Stuart S. Kaufman,David F. Mercer,Mikko P. Pakarinen,Robert S. Venick,Paul W. Wales,Andrew A. Grimm

DOI: https://doi.org/10.1002/jpen.1690

2019-09-08

Journal of Parenteral and Enteral Nutrition

Abstract:<article><section class="article-section article-section__abstract"><h3 class="article-section__sub-title section1"> Background</h3><p>This study evaluated the safety and efficacy of teduglutide in pediatric patients with short bowel syndrome–associated intestinal failure (SBS‐IF).</p><h3 class="article-section__sub-title section1"> Methods</h3><p>A 24‐week, phase III trial with 2 randomized, double‐blind teduglutide dose groups and a nonblinded standard of care (SOC) arm was used; patients received 0.025 mg/kg or 0.05 mg/kg teduglutide once daily. Safety end points included treatment‐emergent adverse events (TEAEs) and growth parameters. The primary efficacy/pharmacodynamic end point was the number of patients who achieved a ≥20% reduction in parenteral support (PS) from baseline at week 24.</p><h3 class="article-section__sub-title section1"> Results</h3><p>All 59 enrolled patients completed the study (0.025 mg/kg, n = 24; 0.05 mg/kg, n = 26; SOC, n = 9). Baseline demographics and disease characteristics were comparable among groups. TEAEs were reported by 98% and 100% of patients in the teduglutide and SOC groups, respectively. The most common TEAEs in the teduglutide‐treated groups were pyrexia and vomiting. The primary end point was achieved by 13 (54.2%), 18 (69.2%), and 1 (11.1%) patients who received 0.025 mg/kg teduglutide, 0.05 mg/kg teduglutide, and SOC, respectively (<i>P</i> < 0.05 vs SOC). Both 0.025‐mg/kg and 0.05‐mg/kg teduglutide groups showed clinically significant reductions in PS volume (<i>P</i> < 0.05 vs SOC), PS calories, days per week and hours per day of PS infusions, and increases in enteral nutrition and plasma citrulline at week 24 compared with baseline. Two (8.3%, 0.025 mg/kg teduglutide) and 3 patients (11.5%, 0.05 mg/kg teduglutide) achieved enteral autonomy. </p><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The safety profile of teduglutide was similar to that reported previously in children and adults. Treatment with teduglutide was associated with significant reductions in PS for pediatric patients with SBS‐IF over 24 weeks.</p></section><section class="article-section article-section__full"><h2 class="article-section__title section__title section1"> Clinical Relevancy Statement</h2><p>Parenteral support (PS)–dependent children with short bowel syndrome–associated intestinal failure (SBS‐IF) have a high disease burden. In this 24‐week, phase III study of 2 randomized, double‐blind teduglutide dose groups and a nonblinded standard of care group, treatment with teduglutide reduced PS volume, calories, and infusion time in pediatric patients with SBS‐IF. The safety profile was consistent with previous experience in adults and children with SBS‐IF. In conjunction with expert management by intestinal rehabilitation specialists in this study, daily teduglutide injection was well tolerated and promoted intestinal adaptation, as evidenced by reductions of PS requirements in children with SBS‐IF.</p><h2 class="article-section__title section__title section1"> Introduction</h2><p>Short bowel syndrome (SBS) is the most common cause of intestinal failure (IF), defined as gut function inadequate for satisfactory absorption of macronutrients, water, or electrolytes to maintain growth and development.<span><a class="bibLink tab-link" href="#jpen1690-bib-0001">1</a></span> Long‐term administration of parenteral support (PS; parenteral nutrition and/or intravenous fluids) is life‐saving but associated with potentially life‐threatening complications, including IF‐associated liver disease, central line–associated blood stream infections, and central venous thrombosis.<span><a class="bibLink tab-link" href="#jpen1690-bib-0001">1</a>-<a class="bibLink tab-link" href="#jpen1690-bib-0003">3</a></span> Enhancing intestinal adaptation minimizes dependence on PS, thereby reducing the risk of complications<span><a class="bibLink tab-link" href="#jpen1690-bib-0004">4</a>-<a class="bibLink tab-link" href="#jpen1690-bib-0006">6</a></span> and potentially improving quality of life.<span><a class="bibLink tab-link" href="#jpen1690-bib-0007">7</a>, <a class="bibLink tab-link" href="#jpen1690-bib-0008">8</a></span></p><p>Glucagon‐like peptide‐2 (GLP‐2), a hormone secreted by enteroendocrine L cells in the distal ileum and proximal colon in response to the presence of unabsorbed luminal nutrients,<span><a class="bibLink tab-link" href="#jpen1690-bib-0009">9</a>, <a class="bibLink tab-link" href="#jpen1690-bib-0010">10</a></span> is a key component of the adaptive response to intestinal malabsorption.<span><a class="bibLink tab-link" href="#jpen1690-bib-0009">9</a>-<a class="bibLink tab-link" href="#jpen1690-bib-0012">12</a></span> Teduglutide, a recombinant human GLP‐2 analogue, is approved in the United States and Europe for the treatment of patients ≥1 year of age with SBS‐IF at a dose of 0.05 mg/kg <p>-Abstract Truncated-</p>

nutrition & dietetics
Growth Hormone for Intestinal Adaptation in Patients with Short Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ming-Xiao Guo,You-Sheng Li,Lei Fan,Jie-Shou Li

DOI: https://doi.org/10.1016/j.curtheres.2011.04.002

2011-01-01

Abstract:OBJECTIVES:The purpose of this systematic review was to assess the efficacy of growth hormone (GH) treatment in patients with short bowel syndrome (SBS).METHODS:Electronic searches were performed to identify all publications describing randomized controlled trials (RCTs) on the use of GH with or without glutamine for the treatment of patients with SBS. The outcomes of interest were body weight, lean body mass, and intestinal absorption function.RESULTS:Four trials involving 70 patients were included in the review. A meta-analysis of these trials suggested that GH had a positive effect in terms of increased weight (mean difference [MD] = 1.66; 95% CI, 0.69-2.63, P < 0.001), lean body mass (MD = 1.93; 95% CI, 0.97-2.90; P < 0.001), energy absorption (MD = 4.42; 95% CI, 0.26-8.58; P = 0.04), nitrogen absorption (MD = 4.85; 95% CI, 0.20-9.49; P = 0.04), and fat absorption (MD = 5.02; 95% CI, 0.21-9.82; P = 0.04) for patients with SBS. Adverse effects occurred during active treatment in all trials. Only 1 trial included a 12-week follow-up study.CONCLUSIONS:The results suggest a possible short-term benefit in terms of body weight, lean body mass, and absorptive capacities; however, no conclusion of long-term efficacy of GH could be obtained. Large-scale, long-term follow-up RCTs are needed to confirm the efficacy and tolerability of GH in the future.
Sacral nerve stimulation effect on colonic motility in pediatric patients

Lev Dorfman,Anat Sigal,Khalil El-Chammas,Sherief Mansi,Ajay Kaul

DOI: https://doi.org/10.4103/sjg.sjg_407_23

2024-03-15

Saudi Journal of Gastroenterology

Abstract:Abstract Background: Sacral nerve stimulation (SNS) is a minimally invasive surgical procedure used to treat refractory constipation in children. While its efficacy in improving symptoms has been studied, its effect on colonic motor function remains unclear. This case series explores SNS’s impact on colonic motor function in pediatric patients with idiopathic constipation, using high-resolution colonic manometry (HRCM). Methods: Four pediatric patients with chronic idiopathic constipation underwent SNS placement for intractable symptoms and were subsequently evaluated via HRCM. Clinical characteristics, comorbidities, treatment regimens, and outcomes were reviewed. HRCM was conducted during the SNS-off and SNS-on phases. The motility index (MI) was measured during the SNS-off (fasting and postprandial) and SNS-on phases. Results: Four pediatric patients aged 8 to 21 years met the inclusion criteria. In three patients, SNS-induced high-amplitude propagating contractions (HAPCs) were noted, and in one patient, low-amplitude propagating contractions (LAPCs) were noted. In one patient, propagating contractions were induced only when SNS was turned on. MI changes with SNS-on were variable among different patients with an increase in MI in two patients after turning SNS on and a decrease in the other two compared with baseline. Adverse effects following SNS placement remained minimal across all cases. Conclusion: This case series is the first to report SNS effects on colonic motility evaluated by HRCM in pediatrics. We demonstrate that propagating colonic contractions are promptly induced when SNS is turned on. Although the initial effects of SNS on colonic motility were observable, additional investigation is necessary to comprehend the fundamental mechanisms and long-term effectiveness of SNS in pediatric patients.

gastroenterology & hepatology
Achieving Digestive Autonomy and Gastrointestinal Continuity in a Patient with Short Bowel Syndrome Secondary to Concomitant Jejunal Atresia and Small Intestinal Hirschsprung's Disease

Alejandro R Velasquez,Thomas O Xu,Yu-Ting Liu,Sulaiman Kidwai,Teresa L Russell,Laura Tiusaba,Krystal Artis,Anthony Sandler,Andrea Badillo,Marc A Levitt

DOI: https://doi.org/10.1055/a-2351-9413

2024-07-16

Abstract:Concomitant presentation of jejunal atresia and Hirschsprung's disease is rare and places children at high risk for developing short bowel syndrome and parenteral nutrition dependence, which can affect the feasibility/timing of pull-through. A patient was born with jejunal atresia with a delayed diagnosis of Hirschsprung's disease. After several procedures and bowel resections, the patient was ultimately left with an end jejunostomy and long Hartman's pouch with short bowel syndrome, dependent on parenteral nutrition. The patient initially presented to our institution at age 2 with failure to thrive secondary to an obstructed/dilated jejunostomy and mild enterocolitis of their defunctionalized segment. The patient subsequently underwent completion of subtotal colectomy and revision of jejunostomy utilizing a serial transverse enteroplasty to manage the dilated bowel and gain length. The patient was able to wean off parenteral nutrition and achieve nutritional autonomy by age 5. Following this, the patient was able to undergo an ileoanal pull-through. After the pull-through, the patient was able to pass stool independently and suffered no major complications to date. Serial transverse enteroplasty can be successfully utilized in patients with a history of Hirschsprung's disease and jejunal atresia to achieve nutritional autonomy and ultimately reestablish gastrointestinal continuity with pull-through.

A SYNTHESIS OF URBAN TRAVEL PATTERNS IN METROPOLITAN LAFAYETTE

Early Intestinal Rehabilitation Therapy Ameliorates Intestinal Adaptation in Children with Short Bowel Syndrome: The Long-Term Outcome

Cisapride Prevents Enteric Bacterial Overgrowth and Translocation by Improvement of Intestinal Motility in Rats with Acute Liver Failure

Influence of Cisapride on Gastric Emptying of Solids and Liquids Monitored by 13C Breath Tests.

Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children

A Review of Enteral Strategies in Infant Short Bowel Syndrome: Evidence-based or NICU Culture?

Polyvalent DNA vaccines with bidirectional promoters

Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis

Impact of intestinal lengthening on the nutritional outcome for children with short bowel syndrome

Effect of Growth Hormone, Glutamine, and Enteral Nutrition on Intestinal Adaptation in Patients with Short Bowel Syndrome

Treatment of Erythromycin and Cisapride for Neonates with Feeding Intolerance

Outcomes of Children With Short Bowel Syndrome: Experiences in a Multidisciplinary Intestinal Rehabilitation Unit Over Two Decades

Serial Transverse Enteroplasty (STEP) for Short Bowel Syndrome (SBS) in Children: A Multicenter Study on Long-term Outcomes

Commentary: Endovascular Repair of Postdissection Aneurysms Involving the Thoracoabdominal Aorta

Effects of Bowel Rehabilitation and Combined Trophic Therapy on Intestinal Adaptation in Short Bowel Patients.

Teduglutide for pediatric short bowel syndrome patients

Long‐term teduglutide associated with improved response in pediatric short bowel syndrome‐associated intestinal failure

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study

Growth Hormone for Intestinal Adaptation in Patients with Short Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Sacral nerve stimulation effect on colonic motility in pediatric patients

Achieving Digestive Autonomy and Gastrointestinal Continuity in a Patient with Short Bowel Syndrome Secondary to Concomitant Jejunal Atresia and Small Intestinal Hirschsprung's Disease